CN103421708A - Strangles streptococcus strain XZ1 and application of strangles streptococcus strain XZ1 in strangles vaccine - Google Patents
Strangles streptococcus strain XZ1 and application of strangles streptococcus strain XZ1 in strangles vaccine Download PDFInfo
- Publication number
- CN103421708A CN103421708A CN2013103093709A CN201310309370A CN103421708A CN 103421708 A CN103421708 A CN 103421708A CN 2013103093709 A CN2013103093709 A CN 2013103093709A CN 201310309370 A CN201310309370 A CN 201310309370A CN 103421708 A CN103421708 A CN 103421708A
- Authority
- CN
- China
- Prior art keywords
- strangles
- streptococcus
- equi
- strain
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to a strain of strangles streptococcus (also known as streptococcus. equi subsp equi) XZ1 with the preservation number of CGMCC No.7830. The strangles streptococcus strain has the16S rRNA gene sequence shown in the sequence table 1; the strain is isolated from sick horses with strangles and has gram positive bacteria, and cells are spherical and are arranged in pairs or cells are bent chain-shaped, which are in poor growth in ordinary broth and plate; beta type hemolysis happens on a plate with 5% of sheep blood, and a completely transparent hemolytic tape with the width of 3 mm can be formed around small dewdrop-shaped bacterial colonies; facultative anaerobic growth can be realized with the growth temperature from 25 DEG C to 40 DEG C, and the optimum growth temperature is 37 DEG C, and the optimum pH value for growth is between 7.4 and 7.5; glucose is fermented for production of acid, and lactose, mannitol and sorbitol cannot be fermented. The strangles streptococcus strain can be used for preparation of strangles inactivated vaccine, and the prepared strangles inactivated vaccine is good in pertinence, low in cost, safe and good in protection effect.
Description
Technical field
A strain provided by the invention separates from strangles suis (Streptococcus.equi subsp equi) the XZ1 bacterial strain CGMCC of Yili of Xinjiang No.7830, and this bacterial strain in the control of strangles, prepare inactivated vaccine method and possible application.
Technical background
Along with economic globalization, modern horse industry has changed the huge enterprise of puting on display, drive the forms such as amusement with horse racing, performance into, and this has welcome unprecedented opportunity to develop for Chinese horse industry.The fast development of horse industry, the raising of horse is mass-producing and intensive increasingly, makes the harm of strangles show to such an extent that become clear day by day.
Strangles (Stangles) is to be caused a kind of acute contagious disease of equus by the strangles suis, is mainly purulent lymphangitis to occur in Horse Neck section and head.This disease is commonly called as spray larynx or groove knot, the larynx bone is swollen, is a kind of acute, the hot transmissible disease by the microbial equus of strangles hammer.It is characterized in that acute, the suppurative inflammation of acute, Catarrhal, suppurative inflammation and neck inferior gluteal lymph node occur the mucous membrane such as nasopharynx.
This disease is high at horse keeping area sickness rate, is worldwide distribution, almost all wants once popular every year, not only directly affects growing of horses, also can cause the death of horses, has caused serious financial loss, is still perplexing the development of horse keeping industry at present.At present the control of this disease in most cases be take to antibiotic therapy and environmental health and control as main, but antibiotic therapy often can cause unsatisfactory curative effect because of bacteriogenic resistance.
The streptococcic vaccine of application strangles can prevent and reduce the generation of this disease to a certain extent.At present domestic aspect the streptococcic commercial vaccine of strangles research and product few, can not adapt to the demand of horse industry fast development.Because the popular bacterial strain in different areas is not quite similar, between different epidemic strains, mutual immunological competence also has different, finds that in addition this class bacterial strain has the characteristics of variation, only is difficult to reach the generation of this disease of effective control different areas with a kind of vaccine strain in addition.For adapting to the fast development of horse aquaculture, purify as early as possible this disease and the generation of controlling this bacterium and popular, need to take the pathological material of disease of Yili of Xinjiang strangles morbidity horses, isolate local popular strangles suis, carry out the researchs such as biochemistry and Molecular Identification, this bacterial strain should be the popular bacterial strain of Yili of Xinjiang, can be used for preparing strangles suis deactivation vaccine, realizes the effective control to local strangles.
Goal of the invention
For in current horse industry development with in the horse disease prevention and control, being badly in need of solving the problem of preventing and treating to strangles, the present invention aims to provide a kind of strangles vaccine strains with strong points, and this bacterial strain can be utilized to prepare strangles suis deactivation vaccine, and this vaccine cost is low, safety, can be used for the prevention of strangles.
Summary of the invention
Strangles suis provided by the invention (Streptococcus.equi subsp equi) XZ1 bacterial strain, on June 28th, 2013, be preserved in No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City institute of microbiology of the Chinese Academy of Sciences " China Committee for Culture Collection of Microorganisms's common micro-organisms " center ", its preserving number is CGMCC No.7830 in Beijing.
1. strangles suis provided by the invention (Streptococcus.equi subsp equi) XZ1 bacterial strain CGMCC No.7830 has following characteristics:
(1) colony characteristics: the tiny bacterium colony that forms canescence, smooth surface, neat in edge on blood agar plate.
(2) cell morphological characteristic: cell circle or oval, general majority is catenation, and 4～8 bacteriums of short person form, and the elder is comprised of 20～30 bacteriums, Gram-positive.
(3) physiological and biochemical property: nutritional requirement is higher, and needing to be added with blood, serum, glucose etc. in ordinary culture medium could grow.Aerobic or amphimicrobian is grown growth temperature from 25 ℃ to 40 ℃, 37 ℃ of optimum temperutures, pH growth scope 6-9, optimal pH 7.4～7.6.
(4) 16S rRNA gene sequence characteristic sees attached list 1.
With reference to " Bergey ' s Manual of Systematic Bacteriology " (second edition), according to its morphological specificity and physiological and biochemical property, and according to the Search Results of its 16S rRNA gene order in GenBank, strangles strains of streptococcus XZ1CGMCC No.7830) be accredited as streptococcus equi horse subspecies (Streptococcus.equi subsp equi).
The substratum TM of CGMCC No.7830 bacterial strain provided by the invention forms:
After PH=7.4112 ℃ of sterilizing in 30 minutes, be prepared from.
2. the preparation of inactivation antigen
Isolate is inoculated in respectively in the TM substratum that is added with 2% horse serum, 37 ℃, 180 r/min cultivation 18～24h, add 0.4% formalin-inactivated 36～48h.The centrifugal supernatant that goes.Bacterial precipitation is diluted to 1 * 10 with sterilizing PBS (pH7.2,10mmol)
7CFU/mL.With immunizing rabbit after the emulsification of equivalent Fu Shi Freund's complete adjuvant, after 3 weeks, with bacterium and the emulsification of equivalent Fu Shi Freunds incomplete adjuvant of same concentration, prepare immunogen.
3. steriling test is inoculated in respectively sheep blood agar plate by the inactivation antigen of preparation, cultivates 24～72h for 37 ℃, observes and has or not bacterial growth:
4. safety examination
By 5 of the rabbit of inactivation antigen subcutaneous injection 1.5～2.0kg body weight of preparation, 4mL/ only, separately gets 2 subcutaneous injection physiological saline and compares, and 4mL/ only, observes 10d.
5. mouse immuning test
Isolate is inoculated in respectively in the TM substratum that is added with 2% horse serum, 37 ℃, 180r/min are cultivated 18～24h, add 0.4% formalin-inactivated 36～48h.The centrifugal supernatant that goes.Bacterial precipitation is diluted to 1 * 10 with sterilizing PBS (pH7.2,10mmol)
6CFU/mL.After steriling test and safety verification, qualified inactivated bacterial liquid and Fu Shi Freund's complete adjuvant and the emulsification of Fu Shi Freunds incomplete adjuvant of equivalent prepare immunogen.By 8 of the mouse of the inactivation antigen subcutaneous injection 20g body weight of preparation, 0.5mL/ only, separately gets 8 of same mouse, skin subcutaneous injection physiological saline compares, and only, each group is all carried out the 2nd immunity to 0.5mL/ after head exempts from after 3 weeks, 2 exempt from rear 15d attacks with live strain, and challenge dose is 1 * 10
5CFU.
5. vaccine valence is measured
Under identical raising condition, 5 of the rabbit of random selection 1.5～2.0kg body weight, back subcutaneous multi-point injection vaccine 4mL/ only, separately getting 5 subcutaneous injection physiological saline compares, 4mL/ only, each group is all carried out the 2nd immunity after head exempts from after 3 weeks, and 15,30,45d makes envelope antigen with thalline, the ELISA method detects antibody.
The invention effect
(1) the invention provides a strain and separate from Yili of Xinjiang strangles suis advantage epidemic strain, the strangles caused for the local popular bacterial strain of effective prevention has important value.The inactivated vaccine production cost prepared with it is low, and added value of product is high, and the market requirement is high, and good market outlook are arranged.
(2) this bacterial strain can be utilized to produce various dissimilar strangles vaccines and comprises inactivated vaccine and subunit vaccine.This vaccine immunization is effective, with strong points, and characteristic is strong.
(3) the invention provides a strain and separate the strangles suis from the sick Malaysia and China of strangles of Yili of Xinjiang, this vaccine is because of with the thorough deactivation of formaldehyde, and the inactivated vaccine security prepared with it is good, dangerous without loose poison.
The accompanying drawing explanation
Fig. 1 is that the streptococcic genomic dna of strangles extracted carries out electrophoresis result figure in 1% sepharose.
Fig. 2 is the electrophoresis result figure of strangles suis 16SrRNA pcr amplification product.
Specific embodiments
In order to understand better the present invention, be further described by following embodiment, but be not limitation of the invention.
Embodiment 1: cultivation and the biological property of strangles strains of streptococcus XZ1CGMCCNo.7830.
Streptococcus equi horse subspecies XZ1CGMCC No.7830 separates the pus from the sick horse of strangles, and being inoculated in blood is in the substrate cultivation base, in 37 ℃ of cultivations, 12-15h.This bacterium has following characteristics: (1) colony characteristics: the colony diameter of cultivating 1 day on the blood agar flat board is 0.2-1.0mm, and bacterium colony is rounded, smooth surface, neat in edge, projection, canescence.(2) cell morphological characteristic: cell is circle or oval; Gram-positive; Cell dia 1.0-2.0 μ m.(3) physiological and biochemical property: amphimicrobian growth; Growth temperature is from 28 ℃ to 39 ℃, 37 ℃ of optimum growth temperatures; PH growth scope 6-8, the most suitable growth pH7.4-7.6; Can glucose fermentation, sucrose, be not hydrolyzed Vitamin C2, in 6.5%NaCl, do not grow, and liquefy gelatin, decompose arginine, can utilize saligenin as carbon source, can not utilize lactose, synanthrin, trehalose, N.F,USP MANNITOL, sorbyl alcohol.
With reference to " Bergey ' s Mannual of Systematic Bacteriology " (second edition), according to its morphological specificity and physiological and biochemical property, and according to the Search Results of its 16S rRNA gene order in GenBank, strain X Z1CGMCC No.7830 is accredited as strangles strains of streptococcus (streptococcus equi horse subspecies, Streptococcus.equi subsp equi).
Embodiment 2: pcr amplification and the sequencing of the 16S rRNA gene of strangles strains of streptococcus XZ1CGMCC No.7830
Strangles strains of streptococcus XZ1CGMCC No.7830 is inoculated in liquid nutrient medium, by growing to logarithm fermented liquid centrifugal (5000 rev/mins, 5 minutes) the removal supernatant liquor in late period, with TE (50mM Tris, 50mM EDTA-Na
2) solution washes 2 times; With 0.5mL TES solution, thalline is mixed, add appropriate N,O-Diacetylmuramidase, 37 ℃ are incubated 2 hours; Add 0.2mL20%SDS, 60 ℃ are incubated 10 minutes; Add 0.3mL5M NaClO
4, mix; Add equal-volume phenol-chloroform-primary isoamyl alcohol (25: 24: 1), shake up gently about 5 minutes, centrifugal (5000 rev/mins, 5 minutes), draw supernatant liquor, then use phenol-chloroform-primary isoamyl alcohol (25: 24: 1) to process one time; Then use successively chloroform-primary isoamyl alcohol (24: 1, v/v) process twice, until do not have protein film to occur; Supernatant liquor adds 37 ℃ of insulations of 20 μ l0.2%RNA enzyme 30 minutes, and chloroform-primary isoamyl alcohol (24: 1, v/v) process three times; Supernatant liquor precipitates with 2 times of volume ice ethanol, 70% ice alcohol solution dipping 5 minutes.After drying, be dissolved in TE solution as template.
The forward primer that is used for the PCR reaction of 16S rRNA gene amplification is:
5 '-TGGAACGCACAGATGATAC-3 ', reverse primer is:
5’-GACTTCGGGTGTTACAAAC-3’。
PCR reaction system (50 μ l) is: 10 * buffer5 μ l, 25mmol/L MgCl
24 μ l, 10mmol/L dNTPs1 μ l, 20pmol/L primer each 1 μ l, ddH
2O36 μ l, Taq DNA enzyme 1 μ l, template 1 μ l.The PCR reaction conditions is: 95 ℃ of 10min, 95 ℃ of 1min, 55 ℃ of 1min, 72 ℃ of 1min, 30 circulations; 72 ℃ of 10min, 4 ℃ of preservations.16S rRNA gene order length is 1312bp.The nucleotide sequence of its 16SrRNA gene is as shown in sequence table 1.
Embodiment 3: the preparation of inactivation antigen
Isolate is inoculated in respectively in the TM substratum that is added with 2% horse serum, 37 ℃, 180r/min are cultivated 18～24h, add 0.4% formalin-inactivated 36～48h.After deactivation thoroughly, 7000rpm/min is centrifugal, and 15min removes supernatant.Bacterial precipitation is diluted to 1 * 10 with sterilizing PBS (pH7.2,10mmol)
7CFU/mL.With immunizing rabbit after the emulsification of equivalent Fu Shi Freund's complete adjuvant, after 3 weeks, with bacterium and the emulsification of equivalent Fu Shi Freunds incomplete adjuvant of same concentration, vaccine carries out steriling test and safety examination after fully vibrating and mixing.
Embodiment 4: steriling test
The inactivation antigen of preparation is inoculated in respectively to sheep blood agar plate, cultivates 24～72h for 37 ℃, observe and have or not bacterial growth.After cultivating, result all loses bacteria growing, shows that inactivating efficacy is good, and working specification is pollution-free.
Embodiment 5: safety examination
By 5 of the rabbit of inactivation antigen subcutaneous injection 1.5～2.0kg body weight of preparation, 4mL/ only, separately gets 2 subcutaneous injection physiological saline and compares, and 4mL/ only, observes 10d.The inoculation rabbit is dead without 1 example, illustrates that vaccine safety is better; Check the reaction of inoculation part and whole body, the rabbit of result all the other inoculations except 1 inoculation position has the light inflammation reaction is without significantly part and systemic reaction, and spirit, body temperature, appetite, breathing and pulse are normal.
Embodiment 6: mouse immuning test
Aldehyde deactivation 36～48h.The centrifugal supernatant that goes.Bacterial precipitation is diluted to 1 * 10 with sterilizing PBS (pH7.2,10mmol)
6CFU/mL.After steriling test and safety verification, qualified inactivated bacterial liquid and Fu Shi Freund's complete adjuvant and the emulsification of Fu Shi Freunds incomplete adjuvant of equivalent prepare immunogen.By 20 of the mouse of the inactivation antigen subcutaneous injection 20g body weight of preparation, 0.5mL/ only, separately get 20 of same mouse, subcutaneous injection physiological saline compares, 0.5mL/ only, each group is all carried out the 2nd immunity after head exempts from after 3 weeks, 2 exempt from rear 15d attacks with the viable bacteria culture of lethal dose, and the dosage of every group of intraperitoneal inoculation attack bacterium is 5 * 10
5CFU, observe one week.Control group is all dead as a result, dead 4 of immune group, and the immune protective efficiency of immune group can reach 80%.
Embodiment 7: vaccine valence is measured
Under identical raising condition, select at random 5 of the rabbit of 1.5～2.0kg body weight, back subcutaneous multi-point injection vaccine 4mL/ only, separately gets 5 subcutaneous injection physiological saline and compares, and only, each group is all carried out the 2nd immunity to 4mL/ after head exempts from after 3 weeks, and 45d is with 10
8Thalline is made envelope antigen, and the ELISA method detects antibody.Detected result shows that the antibody titer of rabbit 45d after twice immunity is 7.3 * 10
5.
Evidence: the inactivated vaccine prepared by this bacterium is to laboratory animal safety, and toxicity is little, and non-evident effect can produce higher immunizing potency after immunizing rabbit 2 times, and 2 ELISA after exempting from tire and can reach 7.3 * 10
5, to the protection ratio of laboratory animal mouse, can reach 80%.
Claims (5)
1. a strain causes strangles suis (claiming the again streptococcus equi horse subspecies Streptococcus.equisubsp equi) XZ1CGMCCNo.7830 of equus strangles.
2. strangles suis according to claim 1 (StTeptococcus.equi subsp equi) XZ1, CGMCC No.7830, is characterized in that the popular bacterial strain for Yili of Xinjiang.Its 16S rDNA has the nucleotide sequence as shown in sequence table 1.
3. strangles suis according to claim 1 (Streptococcus.equi subsp equi) XZ1 CGMCCNo.7830, this bacterial strain can utilize substratum TM grow and obtain.
4. substratum TM substratum according to claim 3 (1000ml) comprising:
After 121 ℃ of sterilizings in 20 minutes of PH=7.4, be prepared from.
5. according to claim 1,2 described strangles suis (Streptococcus.equi subsp equi) XZ1 CGMCC No.7830, can be used for preparing the inactivated vaccine of the local strangles of anti-system.Its preparation method is as follows:
(1) the strangles strains of streptococcus XZ1 that chooses accreditation, as Vaccine strains, is inoculated in the TM substratum that is added with 5% horse serum, and 37 ℃, 180r/min are cultivated 18～24h, add 0.4% formalin-inactivated 36～48h.The centrifugal supernatant that goes.
(2) bacterial precipitation is diluted to 1 * 10 with sterilizing PBS (pH7.2,10mmol)
8CFU/mL.After steriling test and safety verification, qualified inactivated bacterial liquid and Fu Shi Freund's complete adjuvant and the emulsification of Fu Shi Freunds incomplete adjuvant of equivalent are prepared into inactivated vaccine.
(3) inactivated vaccine of gained carried out to steriling test, safety examination and the check of tiring, protection check.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310309370.9A CN103421708B (en) | 2013-07-23 | 2013-07-23 | One strain strangles strains of streptococcus XZ1 and the application in strangles vaccine thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310309370.9A CN103421708B (en) | 2013-07-23 | 2013-07-23 | One strain strangles strains of streptococcus XZ1 and the application in strangles vaccine thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103421708A true CN103421708A (en) | 2013-12-04 |
| CN103421708B CN103421708B (en) | 2016-02-24 |
Family
ID=49647103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310309370.9A Active CN103421708B (en) | 2013-07-23 | 2013-07-23 | One strain strangles strains of streptococcus XZ1 and the application in strangles vaccine thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103421708B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104789587A (en) * | 2015-04-10 | 2015-07-22 | 新疆农业大学 | Application of recombinant eukaryotic expression vector composition in preparation of streptococcus equinus vaccine |
| CN108220182A (en) * | 2016-12-22 | 2018-06-29 | 新疆农业大学 | One plant of horse source streptococcus zooepidemicus strain X JMSY16-1 and its application in streptococcus equi disease vaccine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833723A (en) * | 2006-04-25 | 2006-09-20 | 范红结 | Chain coccus recombination subunit vaccine and prepn. thereof |
| WO2010069335A2 (en) * | 2008-12-19 | 2010-06-24 | Københavns Universitet | Diagnosis of endometritis |
-
2013
- 2013-07-23 CN CN201310309370.9A patent/CN103421708B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833723A (en) * | 2006-04-25 | 2006-09-20 | 范红结 | Chain coccus recombination subunit vaccine and prepn. thereof |
| WO2010069335A2 (en) * | 2008-12-19 | 2010-06-24 | Københavns Universitet | Diagnosis of endometritis |
Non-Patent Citations (1)
| Title |
|---|
| 康立超，等: "马腺疫链球菌的分离鉴定与疫苗的研制", 《黑龙江畜牧兽医》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104789587A (en) * | 2015-04-10 | 2015-07-22 | 新疆农业大学 | Application of recombinant eukaryotic expression vector composition in preparation of streptococcus equinus vaccine |
| CN104789587B (en) * | 2015-04-10 | 2018-04-27 | 新疆农业大学 | Eukaryotic expression recombinant plasmid compound is preparing the application of strangles hammer bacteria vaccine |
| CN108220182A (en) * | 2016-12-22 | 2018-06-29 | 新疆农业大学 | One plant of horse source streptococcus zooepidemicus strain X JMSY16-1 and its application in streptococcus equi disease vaccine |
| CN108220182B (en) * | 2016-12-22 | 2021-02-26 | 新疆农业大学 | Streptococcum zooepidemicus strain XJMSY16-1 and application thereof in streptococcus equi vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103421708B (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113170842B (en) | Composite microecological preparation for preventing and treating necrotic enteritis of poultry and application thereof | |
| CN102399724B (en) | Haemophilus parasuis LC strain and application thereof | |
| CN102847146B (en) | Vaccine used for preventing tilapia streptococcal disease | |
| CN103031258A (en) | Novel mycoplasma hyopneumoniae bacterial strain and vaccine composition thereof | |
| CN104894009B (en) | One plant of mycoplasma hyopneumoniae strain and its application | |
| CN101892175B (en) | Bovine capsular serotype A Pasteurella mutocida, validation identification and application thereof | |
| CN102851249B (en) | Haemophilus parasuis LZ-20100109 strain and application thereof | |
| CN109777758B (en) | Bacillus licheniformis HYT-9 with broad-spectrum antibacterial activity and preparation method and application of microbial inoculum thereof | |
| CN108220183B (en) | Salmonella abortus strain SMXJ-97 and application thereof in salmonella abortus vaccine | |
| CN104450556A (en) | Serum-12 type haemophilus lus paradis vaccine strain and application thereof | |
| CN107338208A (en) | A kind of atrophic rhinitis D types produce malicious multocida vaccine strain and its application | |
| CN107753940A (en) | A kind of C. perfringens epsilon toxin recombinant subunit vaccine and its production method | |
| CN103421708B (en) | One strain strangles strains of streptococcus XZ1 and the application in strangles vaccine thereof | |
| CN104450559A (en) | New mycoplasma hyopneumoniae strain and vaccine composite of new mycoplasma hyopneumoniae | |
| CN104450555A (en) | Serum-13 type haemophilus lus paradis vaccine strain and application thereof | |
| CN108220182B (en) | Streptococcum zooepidemicus strain XJMSY16-1 and application thereof in streptococcus equi vaccine | |
| CN101703769B (en) | Novel tetravalent inactivated vaccine for streptococcus suis disease | |
| CN103656634B (en) | Resisting porcine circovirus and porcine contagious pleuropneumonia infect vaccine combination and preparation | |
| CN106520623B (en) | A kind of serum 7-type haemophilus parasuis low virulent strain and its application | |
| CN104945489A (en) | Preparation and application of tilapia-sourced streptococcus agalactiae recombinant BP-2b protein vaccine | |
| CN103157101B (en) | Combined inactivate vaccine for haemophilus parasuis disease and streptococcus suis disease and preparation method for same | |
| CN104450557A (en) | Serum-5 type haemophilus lus paradis vaccine strain and application thereof | |
| CN103865859B (en) | One strain Staphylococcus sciuri, vaccine and preparation method thereof | |
| CN108251341B (en) | Pseudomonas aeruginosa and marine mammal vaccine containing same | |
| CN105749266A (en) | Mink hemorrhagic pneumonia and botulism combined inactivate vaccine and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |